A Rac1 and Rac3 inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

EHop-016

Item No. 21557

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N4-(9-ethyl-9H-carbazol-3-yl)-N2-[3-(4-morpholinyl)propyl]-2,4-pyrimidinediamine
CAS Number
1380432-32-5
Molecular Formula
C25H30N6O
Formula Weight
430.6
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMF:PBS (pH 7.2); (1:7): 0.125DMSO: 10 mg/ml
λmax
232, 305 nm
SMILES
CCN(C1=C2C=CC=C1)C(C2=C3)=CC=C3NC4=NC(NCCCN5CCOCC5)=NC=C4
InChi Code
InChI=1S/C25H30N6O/c1-2-31-22-7-4-3-6-20(22)21-18-19(8-9-23(21)31)28-24-10-12-27-25(29-24)26-11-5-13-30-14-16-32-17-15-30/h3-4,6-10,12,18H,2,5,11,13-17H2,1H3,(H2,26,27,28,29)
InChi Key
AFTZZRFCMOAFCR-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $54

    Add

    10 mg

    $96

    Add

    25 mg

    $209

    Add

    50 mg

    $392

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    EHop-016 is an inhibitor of the small Rho GTPases Rac1 and Rac3.1 It inhibits Rac1 activity in MDA-MB-435 breast cancer cells with an IC50 value of 1.1 μM in a Rac1 activation assay.2 At a concentration of 1 μM, EHop-016 inhibits 58% of Rac3 activity, and it inhibits Cdc42 activity but only at higher concentrations (5-10 μM). It also increases Rho GTPase RhoA activity ~1.3-fold at concentrations greater than 2 μM. EHop-016 (2-4 μM) inhibits Rac-regulated functions in MDA-MB-435 cells, including lamellipodia formation and serine/threonine p21-activated kinase 1 (PAK1)-mediated cell migration. In a nude mouse model of breast cancer metastasis, EHop-016 (25 mg/kg) significantly lowers mammary fat pad tumor growth, metastasis, and angiogenesis.3 It also inhibits mutant receptor tyrosine kinase (KIT)-induced growth in systemic mastocytosis and acute myeloid leukemia (AML) cells (≥2.5 μM).4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Dharmawardhane, S., Hernandez, E., and Vlaar, C. Development of EHop-016: A small molecule inhibitor of Rac. Enzymes 33 Pt A, 117-146 (2013).

    2. Montalvo-Ortiz, B.L., Castillo-Pichardo, L., Hernández, E., et al. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase. The Journal of Biological Chemisty 287(16), 13228-13238 (2012).

    3. Castillo-Pichardo, L., Humphries-Bickley, T., De La Parra, C., et al. The Rac inhibitor EHop-016 inhibits mammary tumor growth and metastasis in a nude mouse model. Transl. Oncol. 7(5), 546-555 (2014).

    4. Martin, H., Mali, R.S., Ma, P., et al. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J. Clin. Invest. 123(10), 4449-4463 (2013).